Richard Ramko is a partner in Ernst & Young's South Florida practice, primarily serving publicly-held and emerging growth companies in the Health Sciences, Biotech and Technology industries.
Ramko has extensive experience serving large, publicly-held companies as well as newly formed start-ups and venture-backed enterprises. Richard has 15 years of experience, including 13 years in public accounting and 2 years in executive level financial positions in private industry and is a certified public accountant in Florida and Tennessee. Some of his current clients include Andrx Corporation, Nabi Biopharmaceuticals, Stiefel Laboratories and SFBC International.
As can be seen above, the losses incurred by biotech companies have declined significantly since the early 1990s. 1991's loss was $40 billion while 2005s was approximately $5 billion. I am not going to make a prediction today regarding when the industry will achieve profitability, I think we'll ac...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
